{"id":42592,"date":"2015-02-10T00:00:00","date_gmt":"2015-02-09T23:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/novedad-en-los-fondos-biotecnologicos-en-espana-en-2015\/"},"modified":"2025-03-12T11:25:55","modified_gmt":"2025-03-12T10:25:55","slug":"novedad-en-los-fondos-biotecnologicos-en-espana-en-2015","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/novedad-en-los-fondos-biotecnologicos-en-espana-en-2015\/","title":{"rendered":"New developments in biotech funds in Spain (En-2015)"},"content":{"rendered":"<address><span style=\"color: #000000;\">A small number of venture capitalists specialising in biotechnology are consolidating in Spain. Some of them are receiving support from international investors and others are emerging as a result of the attractiveness of Spain for this sector. Let us look at some examples.<\/span><\/address>\n<p><!--more--><\/p>\n<p><span style=\"color: #3366ff;\"><strong>Ysios makes a first closing of its second fund<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.ysioscapital.com\/\" target=\"_blank\" rel=\"noopener\">Ysios<\/a><\/span> was created in 2008 as the first Spanish venture capital manager specialising in the life sciences sector. It invests both in Spain and abroad. It has recently secured commitments from investors totalling \u20ac51.8M, enabling it to close its second fund with a target of \u20ac100M.<\/span><\/p>\n<p><span style=\"color: #000000;\">\"The big challenge in the fundraising process is replacing banks and savings banks as LPs with new investors. In the case of Ysios, in the first fund, banks accounted for 48% and in this second fund they are not expected to reach 10%,\" says Diego Gutierrez of Ysios.<span style=\"text-decoration: underline;\">e<a href=\"https:\/\/techma.bakertilly.es\/en\/\"> ABRA INVEST.<\/a><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"> Ysios' investors include public institutions such as <span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.cdti.es\/\" target=\"_blank\" rel=\"noopener\">CDTI<\/a>,<\/span> family offices such as Bernat Fo and Vilcasas and financial institutions such as<span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.seguroslagunaro.com\/\" target=\"_blank\" rel=\"noopener\"> Lagun Aro<\/a><\/span>,<span style=\"text-decoration: underline;\"> Sabadell Investment<\/span> and<span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.orza.info\/\" target=\"_blank\" rel=\"noopener\"> Orza.<\/a> \u00a0<\/span><\/span><\/p>\n<p><span style=\"color: #3366ff;\"><strong>CRB inverbio attracts CAF as a new investor<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.crbinverbio.com\/\" target=\"_blank\" rel=\"noopener\">CRB inverbio <\/a><\/span>CRB Inverbio's second fund, CRB Inverbio, was founded in 2010, building on the experience and know-how of Cross Road Biotech, which had invested in 10 biotech companies since 2005, with a first closing of \u20ac30M in 2012, and has recently managed to incorporate CAF as a shareholder with a contribution of \u20ac3.9M, or 11.5% of the total capital under management.<\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.caf.com\/\" target=\"_blank\" rel=\"noopener\">CAF, Andean Development Corporation<\/a><\/span>CAF is a Latin American development bank established in 1970 and made up of 19 countries - 17 Latin American and Caribbean countries plus Spain and Portugal - and 14 private banks. CAF is one of the main sources of multilateral financing and an important generator of knowledge for the region.<\/span><\/p>\n<p><span style=\"color: #000000;\">\"CAF has recently entered into<span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.cofides.es\/\" target=\"_blank\" rel=\"noopener\"> COFIDES<\/a><\/span> by acquiring 1.14% of its share capital at <span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.bbva.es\/particulares\/index.jsp\" target=\"_blank\" rel=\"noopener\">BBVA<\/a>.<\/span> The investment in CRB Inverbio is one of its first forays into specialised venture capital in Spain. Hopefully it will expand its presence in other technological areas,\" says Diego Gutierrez.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"color: #3366ff;\"><strong>Ousul ventures, a new biotech fund <\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Catalan and US executives have just announced the launch of a new fund specialising in biotechnology. Its name is Ousul Ventures and it expects to raise between \u20ac100M and \u20ac150M, mainly from Middle Eastern sovereign wealth funds.<\/span><\/p>\n<p><span style=\"color: #000000;\">The fund's objective is to invest in companies that are able to participate in the creation of a scientific and biomedical research community in the Persian Gulf countries. Advised by<span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.biocat.cat\/es\" target=\"_blank\" rel=\"noopener\"> Biocat<\/a>,<\/span> are also analysing scientific projects developed by Catalan hospitals.<\/span><\/p>\n<p><strong><span style=\"color: #3366ff;\">Other posts that may interest you<\/span><\/strong><\/p>\n<p><span style=\"text-decoration: underline;\"><a href=\"https:\/\/techma.bakertilly.es\/en\/juan-diego-cuenca-socio-de-abra-invest-analiza-el-sector-tecnologico-en-gestionaradio\/\">Juan Diego Cuenca, partner of Abra-invest, analyses the biotechnology sector on Gestionaradio <\/a><\/span><\/p>\n<p style=\"color: #919191;\"><span style=\"text-decoration: underline;\"><span style=\"font-weight: inherit; font-style: inherit;\"><span style=\"font-weight: inherit; font-style: inherit; color: #000000; text-decoration: underline;\"><a style=\"font-weight: inherit; font-style: inherit; color: #a1a1a1; text-decoration: underline;\" href=\"https:\/\/techma.bakertilly.es\/en\/merger-and-acquisition-m-a\/\" target=\"_blank\">mergers and acquisitions<\/a>-en-biotecnologia-en-espana\/\"&gt;<span style=\"font-weight: inherit; font-style: inherit; color: #000000; text-decoration: underline;\">List of <a href=\"https:\/\/techma.bakertilly.es\/en\/merger-and-acquisition-m-a\/\" target=\"_blank\">mergers and acquisitions<\/a> in Biotechnology Spain<\/span><\/a><\/span><\/span><\/span><\/p>\n<p style=\"color: #919191;\"><span style=\"text-decoration: underline;\"><span style=\"font-weight: inherit; font-style: inherit;\"><span style=\"font-weight: inherit; font-style: inherit; color: #000000; text-decoration: underline;\"><a style=\"font-weight: inherit; font-style: inherit; color: #272727; text-decoration: underline;\" href=\"http:\/\/logic-fin.com\/listado-de-inversores-en-espana-en-biotecnologia\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: inherit; font-style: inherit; color: #000000; text-decoration: underline;\">List of investors in Spain in Biotechnology<\/span><\/a><\/span><\/span><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>A small number of venture capitalists specialising in biotechnology are consolidating in Spain. Some of them are receiving support from international investors and others are emerging as a result of the attractiveness of Spain for this sector.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2277],"tags":[238,249],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42592","post","type-post","status-publish","format-standard","hentry","category-multiplos-de-empresas-cotizadas","tag-biotecnologia","tag-inversion-en-biotecnologia","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42592"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42592\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42592"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42592"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}